Twist Bioscience Corp
NASDAQ:TWST
Intrinsic Value
Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. [ Read More ]
The intrinsic value of one TWST stock under the Base Case scenario is 48.96 USD. Compared to the current market price of 30.75 USD, Twist Bioscience Corp is Undervalued by 37%.
Valuation Backtest
Twist Bioscience Corp
Run backtest to discover the historical profit from buying and selling TWST stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Twist Bioscience Corp
Current Assets | 390.2m |
Cash & Short-Term Investments | 311.1m |
Receivables | 35.4m |
Other Current Assets | 43.7m |
Non-Current Assets | 342.6m |
PP&E | 195.3m |
Intangibles | 139m |
Other Non-Current Assets | 8.3m |
Current Liabilities | 65.2m |
Accounts Payable | 9.3m |
Accrued Liabilities | 49.6m |
Other Current Liabilities | 6.4m |
Non-Current Liabilities | 77.5m |
Other Non-Current Liabilities | 77.5m |
Earnings Waterfall
Twist Bioscience Corp
Revenue
|
262.4m
USD
|
Cost of Revenue
|
-168.5m
USD
|
Gross Profit
|
93.9m
USD
|
Operating Expenses
|
-297.2m
USD
|
Operating Income
|
-203.3m
USD
|
Other Expenses
|
-2.5m
USD
|
Net Income
|
-205.8m
USD
|
Free Cash Flow Analysis
Twist Bioscience Corp
TWST Profitability Score
Profitability Due Diligence
Twist Bioscience Corp's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Twist Bioscience Corp's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
TWST Solvency Score
Solvency Due Diligence
Twist Bioscience Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Twist Bioscience Corp's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
TWST Price Targets Summary
Twist Bioscience Corp
According to Wall Street analysts, the average 1-year price target for TWST is 40.93 USD with a low forecast of 25.25 USD and a high forecast of 50.4 USD.
Ownership
TWST Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
TWST Price
Twist Bioscience Corp
Average Annual Return | 97.95% |
Standard Deviation of Annual Returns | 293.51% |
Max Drawdown | -94% |
Market Capitalization | 1.8B USD |
Shares Outstanding | 57 820 000 |
Percentage of Shares Shorted | 27.8% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Twist Bioscience Corp. develops proprietary semiconductor-based synthetic DNA manufacturing process. The company is headquartered in South San Francisco, California and currently employs 652 full-time employees. The company went IPO on 2018-10-31. The firm has developed a Twist Bioscience DNA synthesis platform to industrialize the engineering of biology. The core of its platform is a technology that provides a new method of manufacturing synthetic DNA by writing DNA on a silicon chip. The firm has developed multiple products derived from synthetic DNA and its versatile DNA synthesis technology. The company consists of two product lines, synthetic biology tools and NGS tools, that address different needs of its customers across a range of applications, such as synthetic genes, oligo pools, SARS-CoV-2 tools, and DNA libraries. Its synthetic biology products include Synthetic genes, Clonal genes in a Twist Bioscience, Non-clonal genes, Oligonucleotide or Oligo, pools, and Oligo pools for CRISPR gene editing. The NGS products are used for diagnostic tests for various indications like SARS-CoV-2 and cancer through liquid biopsy.
Contact
IPO
Employees
Officers
The intrinsic value of one TWST stock under the Base Case scenario is 48.96 USD.
Compared to the current market price of 30.75 USD, Twist Bioscience Corp is Undervalued by 37%.